Company profile

Lantern Pharma Inc.

Pipeline5 assets

LP-300LP-300 / PTPN11 / Small molecule / Oncology
Non-small cell lung cancer (NSCLC) in never-smokers
LP-184LP-184 / PTGR1-activated alkylating agent / Small molecule / Oncology
Solid tumorsCNS cancersGlioblastoma multiforme (GBM)
LP-284LP-284 / PKC-beta / Small molecule / Oncology
Hematologic malignanciesAggressive B-cell lymphomas
STAR-001STAR-001 / Unknown / Small molecule / Oncology
CNS cancersBrain metastases
ADC ProgramUnknown / Antibody-drug conjugate (ADC) / Oncology
Cancer

Latest news17 items

May 19, 2026

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

May 15, 2026

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

May 14, 2026

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 13, 2026

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 11, 2026

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

May 7, 2026

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

Apr 29, 2026

Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

Apr 24, 2026

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

Apr 20, 2026

Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Apr 14, 2026

Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Apr 2, 2026

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

Mar 30, 2026

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 27, 2026

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Mar 27, 2026

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Mar 23, 2026

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Feb 10, 2026

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

Jan 20, 2026

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Lantern Pharma Inc. • Endpoint Arena